Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab dose-regimen study in moderate to severe hidradenitis suppurativa
2018-002063-26Phase 3Unknown
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (3 arms), sponsored by Novartis. Primary endpoint: Achievement of HiSCR at Week 16. Status: unknown.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2018-002063-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002063-26.